http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3902910-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0efa833f156f24311238f55730cd3c9e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-10023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13022 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-907 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 |
| filingDate | 2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d3af118c014999470da8b20f32ef081 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4c1c59efe93ea9d192d28727485c56c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_460b6745260e683a3fd89067cf5fe9f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a852d75b250cdec4686c5c744962e38d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6eb4abe658a155a3d53d36f4301a06b6 |
| publicationDate | 2021-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3902910-A1 |
| titleOfInvention | Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells |
| abstract | Type-C endogenous retroviruses (ERVs) embedded in Chinese hamster ovary (CHO) cells were altered to modify the release of retroviral and/or retroviral-like particles in the culture supernatant. Although evidence for the infectivity of these particles is missing, their presence has raised safety concerns. 173 type-C ERV sequences that clustered into functionally conserved groups were identified. Transcripts from one type-C ERV group were identified to be full-length with intact open reading frames, and to have corresponding viral RNA genomes that were loaded into retroviral-like particles. Also, sequence analysis of the genomic RNA from viral particles indicated that they may result from few expressed ERV sequences. Disclosed herein is the disruption/alteration of the gag gene of the expressed ERV group using CRISPR-Cas9 genome editing. Comparison of CRISPR-derived mutations at the DNA and mRNA level led to the identification of a single ERV locus responsible for the release of viral RNA-loaded particles from CHO cells. Clones bearing a Gag loss-of-function mutation in this particular ERV locus showed a reduction of viral RNA-containing particles in the cell supernatant by over 250-fold. Notably, ERV mutagenesis did not compromise cell growth, cell size or recombinant protein production. Provided herein is a new strategy and cells, in particular engineered CHO cells, to mitigate potential contaminations from CHO endogenous retroviruses during biopharmaceutical manufacturing. |
| priorityDate | 2018-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 176.